Cargando…

Correction to: Significance of upfront cytoreductive nephrectomy stratified by IMDC risk for metastatic renal cell carcinoma in targeted therapy era – a multi‑institutional retrospective study

Detalles Bibliográficos
Autores principales:	Kato, Renpei, Naito, Sei, Numakura, Kazuyuki, Hatakeyama, Shingo, Koguchi, Tomoyuki, Kojima, Takahiro, Kawasaki, Yoshihide, Kandori, Shuya, Kawamura, Sadafumi, Arai, Yoichi, Ito, Akihiro, Nishiyama, Hiroyuki, Kojima, Yoshiyuki, Ohyama, Chikara, Habuchi, Tomonori, Tsuchiya, Norihiko, Obara, Wataru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Nature Singapore 2023
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10119231/ https://www.ncbi.nlm.nih.gov/pubmed/37010622 http://dx.doi.org/10.1007/s10147-023-02331-z

Ejemplares similares

Significance of upfront cytoreductive nephrectomy stratified by IMDC risk for metastatic renal cell carcinoma in targeted therapy era – a multi-institutional retrospective study
por: Kato, Renpei, et al.
Publicado: (2022)

Outcomes of axitinib versus sunitinib as first‐line therapy to patients with metastatic renal cell carcinoma in the immune‐oncology era
por: Numakura, Kazuyuki, et al.
Publicado: (2021)

Clinical impact of early response to first‐line VEGFR‐TKI in patients with metastatic renal cell carcinoma on survival: A multi‐institutional retrospective study
por: Sobu, Ryuta, et al.
Publicado: (2022)

Impact of pretreatment anemia on upfront abiraterone acetate therapy for metastatic hormone-sensitive prostate cancer: a multicenter retrospective study
por: Okamoto, Teppei, et al.
Publicado: (2021)

Impact of germline HLA genotypes on clinical outcomes in patients with urothelial cancer treated with pembrolizumab
por: Takahashi, Shuhei, et al.
Publicado: (2022)

Host-related Risk Factors for Adherent Perinephric Fat in Healthy Individuals Undergoing Laparoscopic Living-donor Nephrectomy
por: Narita, Shintaro, et al.
Publicado: (2017)

Cytoreductive Nephrectomy in 2021: Obsolete
por: Meza, Luis, et al.
Publicado: (2021)

New Paradigms for Cytoreductive Nephrectomy
por: Lichtbroun, Benjamin J., et al.
Publicado: (2022)

Cytoreductive Nephrectomy and Nephrectomy/Complete Metastasectomy for Metastatic Renal Cancer
por: Russo, Paul, et al.
Publicado: (2007)

Cytoreductive nephrectomy in the current treatment algorithm
por: Kuusk, Teele, et al.
Publicado: (2019)

Cytoreductive Nephrectomy in 2021: Obsolete but Necessary
por: Capitanio, Umberto, et al.
Publicado: (2021)

Cytoreductive Nephrectomy: Still Necessary in 2021
por: Méjean, Arnaud, et al.
Publicado: (2022)

Comparison of upfront versus deferred cytoreductive nephrectomy in patients with metastatic renal cell carcinoma receiving systemic therapy: a systematic review and meta-analysis
por: Li, Kun-peng, et al.
Publicado: (2023)

Insulin-like growth factor-1 genotypes and haplotypes influence the survival of prostate cancer patients with bone metastasis at initial diagnosis
por: Tsuchiya, Norihiko, et al.
Publicado: (2013)

Factors influencing warm ischemia time in robot-assisted partial nephrectomy change depending on the surgeon’s experience
por: Numakura, Kazuyuki, et al.
Publicado: (2022)

Comprehensive characterization of the perioperative morbidity of cytoreductive nephrectomy
por: Leone, Andrew, et al.
Publicado: (2016)

PNI as a Potential Add-On Biomarker to Improve the IMDC Intermediate Prognostic Score
por: Bayoğlu, İbrahim Vedat, et al.
Publicado: (2023)

Erratum to comprehensive characterization of the perioperative morbidity of cytoreductive nephrectomy
Publicado: (2016)

Cytoreductive nephrectomy in the age of immunotherapy-based combination treatment
por: Song, Sang Hun, et al.
Publicado: (2023)

Therapeutic effects of the combined androgen blockade therapy versus luteinizing hormone-releasing hormone analog monotherapy in patients with hormone naïve metastatic prostate cancer: a multi-institutional comparative analysis
por: Narita, Takuma, et al.
Publicado: (2021)

The current role of cytoreductive nephrectomy for metastatic renal cell carcinoma
por: Umbreit, Eric C., et al.
Publicado: (2021)

The Evolving Landscape of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma
por: Studentova, Hana, et al.
Publicado: (2023)

Successful mammalian target of rapamycin inhibitor maintenance therapy following induction chemotherapy with gemcitabine and doxorubicin for metastatic sarcomatoid renal cell carcinoma
por: NUMAKURA, KAZUYUKI, et al.
Publicado: (2014)

Incidence, Etiology, Prevention and Management of Ureteroenteric Strictures after Robot-Assisted Radical Cystectomy: A Review of Published Evidence and Personal Experience
por: Narita, Shintaro, et al.
Publicado: (2021)

Complete remission of brain metastases in renal cell carcinoma treated with axitinib after failure with nivolumab and ipilimumab treatment
por: Takayama, Koichiro, et al.
Publicado: (2022)

Deliberation on Deferred Cytoreductive Nephrectomy and Postoperative Treatment for Advanced Renal Cell Carcinoma: A Case Report
por: Nakagawa, Takuya, et al.
Publicado: (2022)

Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk localized prostate cancer
por: Narita, Shintaro, et al.
Publicado: (2012)

First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC
por: Ko, J J, et al.
Publicado: (2014)

Laparoscopic cytoreductive nephrectomy and adrenalectomy for metachronous RCC metastases—Case report
por: Petrut, Bogdan, et al.
Publicado: (2020)

Complications associated with perioperative use of tyrosine kinase inhibitor in cytoreductive nephrectomy
por: Carvalho, Filipe L. F., et al.
Publicado: (2019)

The role of cytoreductive nephrectomy in renal cell carcinoma patients with liver metastasis
por: Guo, Boda, et al.
Publicado: (2021)

Clinical implications of serum N‐glycan profiling as a diagnostic and prognostic biomarker in germ‐cell tumors
por: Narita, Takuma, et al.
Publicado: (2017)

Impact of Early Exposure to Simulation Program on Undergraduate Medical Students’ Interest in Urology
por: Kimura, Tomokazu, et al.
Publicado: (2021)

Severe Immune-Related Adverse Events in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma Are Associated with PDCD1 Polymorphism
por: Kobayashi, Mizuki, et al.
Publicado: (2022)

Prognostic significance of early changes in serum biomarker levels in patients with newly diagnosed metastatic prostate cancer
por: Narita, Shintaro, et al.
Publicado: (2019)

Changes in conditional net survival and dynamic prognostic factors in patients with newly diagnosed metastatic prostate cancer initially treated with androgen deprivation therapy
por: Narita, Shintaro, et al.
Publicado: (2019)

Is Cytoreductive Nephrectomy Still a Standard of Care in Metastatic Renal Cell Carcinoma?
por: Renner, Alex, et al.
Publicado: (2019)

The Effect of Cytoreductive Partial Nephrectomy in Elderly Patients with Metastatic Renal Cell Carcinoma
por: Chen, Jiabi, et al.
Publicado: (2020)

Predictors of Cytoreductive Nephrectomy for Metastatic Kidney Cancer in SEER and Metropolitan Detroit Databases
por: Vaishampayan, Ulka, et al.
Publicado: (2019)

Cytoreductive Nephrectomy and Metastatic Renal Cell Carcinoma: State of the Art and Future Perspectives
por: Napolitano, Luigi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_h2ivher0nq0alfpr1rsa9fcsil